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ABSTRACT
Background and Objectives: The emergence of extended-spectrum β-lactamase (ESBL)-producing Shigella spp.  is of 
increasing clinical concern specially in children worldwide. The aim of this study was to investigate the occurrence of 
extended-spectrum β-lactamase producing Shigella spp. in Tehran, Iran.
Materials and Methods: The study included all Shigella isolates recovered from pediatric patients aged less than 12 years 
admitted to a major pediatric hospital in Tehran, Iran, from 2008 to 2010. Bacterial identification, antimicrobial susceptibility 
testing, extended spectrum β-lactamases (ESBLs) screening and confirmatory tests were performed according to the standard 
guidelines. Conjugal transfer experiments and plasmid analysis were also carried out. Polymerase chain reaction and 
sequencing were used to identify the genetic determinants responsible for ESBL production.
Results: Four out of 55 Shigella isolates, including three S. sonnei and one S. flexneri, showed an ESBL-positive phenotype.
Plasmid transfer of the ESBL phenotype was successful for the S. flexneri isolate only. By PCR and sequencing, one S. sonnei 






Conclusion: We found the prevalence of ESBL producing Shigella isolates was higher than detection rates observed in 
many other countries. Our finding raise concerns about the dissemination of ESBL among the strains of endemic S. sonnei 
throughout the country, because this species is now the most frequently isolated Shigella species in Iran and shigellosis by 
such strains in the community can pose a significant threat to patients and presents a challenge for disease management.
Keywords: ESBLs, Shigella spp, Antibiotic resistance
INTRODUCTION
Infections caused by Shigella species remain a 
major cause of diarrheal disease associated with high 
morbidity and mortality in developing countries, such 
as Iran (1). Among the four Shigella spp., S. sonnei, 
is the most commonly isolated species particularly in 
industrialized countries (2).
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Adequate antibiotic therapy is helpful in shigellosis 
because it may shorten the clinical course of illness, 
significantly reduce the risk of transmission and 
prevent also potentially lethal complications. However, 
high frequencies of resistance to commonly used 
antimicrobial agents have been reported worldwide in 
Shigella spp. Moreover, the emergence of resistance 
to third-generation cephalosporins (3GC) in Shigella 
spp. is a matter of great public health concern, mainly 
in developing countries (3).
Since the initial report of SHV-11–type β-lactamase 
in S. dysenteriae from India in 1999, Shigella species 
producing CTX-M, SHV, and TEM-type extended 
spectrum β-lactamases (ESBLs) have been identified 
worldwide from different regions (4). Indeed, an 
increasing number of countries, including United 
States, France, Turkey, Lebanon, Bangladesh, Hong 
Kong and China have recently notified the isolation 
of ESBL-producing Shigella isolates (5-11).
There are several reports showing that the frequency 
of resistance against different antibiotic groups other 
than third-generation cephalosporins is increasing 
among the Shigella strains isolated in Iran (12-15).
Here we report the identification and characteriza-
tion of ESBL producing Shigella strains in Tehran, 
Iran.
MATERIALS AND METHODS
Bacterial isolates and antimicrobial susceptibility.
The study included all Shigella isolates recovered 
from pediatric patients aged less than 12 years and 
admitted to Children’s Medical Center in Tehran, 
Iran, from November 2008 to May 2010. A single 
specimen was obtained from each patient, and rectal 
swabs were collected from patients on the day of 
admission at the hospital. All strains were identified 
at a genus level by conventional methods according 
to previously described procedures (16). Serotyping 
of the isolates was performed by slide agglutination 
(Shigella Antisera, Denka Seiken, Tokyo, Japan). 
Antibiotic susceptibility testing was performed 
according to CLSI guidelines (17) using the following 
antibiotic disks (Oxoid, Basingstoke, Hampshire, 
UK): ampicillin (AM, 10 μg), amoxicillin–clavulanic 
acid (AMC, 20–10 μg), cephalotin (CF, 30 μg), 
cefixime (CFM, 5 μg ), cefotaxime (CTX, 30 μg), 
ceftizoxime (CT, 30 μg), ceftriaxone (CRO, 30 μg), 
ceftazidime (CAZ, 30 μg), ciproﬂoxacin (CIP, 5 μg), 
chloramphenicol (C, 30 μg), doxycycline (D, 30 μg), 
gentamicin (GN, 10 mg), kanamycin (K, 10 μg), 
nalidixic acid (NA, 30 μg), neomycin (N, 30 μg), 
nitrofurantoin (FD, 300 μg), piperacillin (PIP, 100 μg), 
streptomycin (S, 10 μg), tetracycline (TE, 30 μg), 
ticarcillin (TIC, 75 μg), tobramycin (TOB, 10 μg), 
trimethoprim–sulfamethoxazole (SXT, 1.25-23.75 μg).
Detection and characterization of ESBLs.
Screening of 3rd generation cephalosporins (3GC) 
resistant Shigella isolates was performed by disk 
diffusion method using ceftazidime, cefotaxime, 
ceftriaxone and cefepime disks. According to CLSI 
criteria for detection of ESBL producers, each isolate 
with inhibition zone diameter ≤22 mm for ceftazidime 
or ≤27 mm for cefotaxime was considered as a 
potential ESBL-producer. Phenotypic confirmation 
of ESBL production was done by double disk synergy 
and combination disk tests (18).  
Escherichia coli ATCC 25922 and previously 
characterized ESBL-positive E. coli, Klebsiella-
pneumoniae and AmpC-positive Enterobacter 
cloacae strains were used as controls for antibiotic 
susceptibility testing and the following ESBL 
analysis. Phenotypic detection of AmpC enzymes 
was performed by using cefoxitin supplemented 
with cloxacillin and E. coli ATCC 25922 according 
to the previously described method (19). In brief, the 
30 μg cefoxitin disk was supplemented with 200 μg of 
cloxacillin (Sigma-Aldrich, Singapore). A strain was 
considered to be an AmpC producer when it showed 
an increase in diameter around the antibiotic disk with 
added cloxacillin compared to that with the cefoxitin 
disk alone. 
A multiplex PCR assay approach was used for a rapid 
screening of frequently encountered β-lactamases 
according to the procedure previously described by 
Dallenneet al. (20). DNA of the isolates under study 
was subjected to the multiplex PCR reactions I to 
III in 50 µL reaction mixtures containing variable 
concentrations of specific-group primers and 1 U 
of Taq polymerase (20). Amplification was carried 
out as follows: initial denaturation at 94°C for 10 min; 
30 cycles of 94°C for 40 s, 60°C for 40 s and 72°C for 
1 min; and a final extension step at 72°C for 7 min. 
Amplicons were visualized on 2% agarose gels. 
To identify the β-lactamase genes detected in the 
multiplex PCR assays, amplicons were purified 
using a QIA quick PCR Purification Kit (Qiagen, 
GmbH, Germany) and bidirectional sequencing 
was performed. The nucleotide sequences and the 
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deduced protein sequences were analyzed with the 
BLAST and Clustal W programs (multiple sequence 
alignment, pairwise comparisons of sequences and 
dendrograms). 
Resistance transfer experiments were performed 
for all four isolates as previously described with the 
rifampicin resistant Escherichia coli K12J5 as the 
recipient. Brieﬂy, mixed cultures of the donors and 
the rifampicin resistant recipient E. coli strain were 
incubated at 37°C overnight. The transconjugants were 
selected on MacConkey agar plates supplemented 
with ceftazidime or cefotaxime- 30 µg/ml - and 
rifampicin - 250 µg/ml.  
A confirmatory test for ESBL and AmpC phenotypes 
and PCR detection for ESBL genes were performed 
on transconjugant colonies by the above mentioned 
procedures. Plasmids from Shigella isolates and 
E. coli transconjugants were extracted by an alkaline 
lysis extraction method (21).
RESULTS
Fifty five Shigella isolates were isolated during 
the study period. Of theses, 51 strains (92.7%) 
were susceptible to 3GC. As shown in Table 1, four 
strains (7.3%), including three S. sonnei and one 
S. flexneri showed concomitant resistance to these 
3GC antibiotics and were selected for ESBL 
production.
Double disk synergy and combination disk tests 
confirmed that these four strains had ESBL-positive 





were detected in the S. flexneri and two S. sonnei 
isolates, whereas the third S. sonnei isolate showed a 
bla
CMY









15, respectively, whilst the CMY ESBL was identified 
as CMY-59.
Based on the conjugation assay, only the 
S. flexneri isolate was able to transfer the bla gene 
to transconjugant, confirming that it was mediated by 
a plasmid of approximately 107MDa (Fig. 1). Only 
resistance to trimethoprim was co-transferred along 
with the ESBL encoding sequence.
DISCUSSION
Ampicillin and sulfamethoxazole-trimethoprim are 
generally indicated as the first-line drugs for therapy 
of shigellosis. However, in the event of disease 
caused by a multidrug resistant strain, second-line 
12
Fig. 1. Plasmid patterns of the Shigella clinical isolates and the transconjugantEscherichia coli
from the S. flexneri isolate. 
Lanes: MW, molecular weight, Escherichia coli 39R861; 1, S. sonnei n.1; 2, S. flexneri n.2; 3, S.
sonnei n. 3; 4, S. sonnei n.4; 5, E. coli K12J5 transconjugant from the S. flexneri isolate n.2.
Fig. 1. Plasmid patterns of the Shigella clinical isolates 
and the transconjugant Escherichia coli from the S. flexneri 
isolate.
Lanes: MW, molecular weight, Escherichia coli 39R861; 1, 
S. sonnei n.1; 2, S. flexneri n.2; 3, S. sonnei n. 3; 4, S. sonnei 
n.4; 5, E. coli K12J5 transconjugant from the S. flexneri 
isolate n.2.
Strain No. Time of isolation Serotype Antibiotic resistance pattern* Type of β-lactamase
1 June 12, 2009 S. sonnei AMC- AM-NA-CAZ- TIC-CTX-CRO-CT-PIP-D-TE-S-SXT-CF CMY-59
2 July 23, 2009 S. flexneri AMC- AM-NA-CAZ- TIC-CTX-CRO-D-TE-S-SXT-C-CF  TEM-1, CTX-M-15
3 September 3, 2009 S. sonnei AMC-AM-NA-CAZ- TOB-TIC-CTX-CRO-PIP-D-TE-S-SXT  TEM-1, CTX-M-15
4 November 10, 2009 S. sonnei AMC-AM-CZA-TOB-TIC-CTX-CRO-D-TE-S-SXT-CF TEM-1, CTX-M-15
Table 1. Characteristics of the ESBL-producing Shigella strains under study.
*AM: ampicillin, AMC: amoxycillin-clavulanic acid, C: chloramphenicol, CAZ: ceftazidime, CF: cephalothin, CRO: 
ceftriaxone, CT: ceftizoxime, CTX: cefotaxime, D: doxycycline,   NA: nalidixic acid, PIP: piperacillin, S: streptomycin, 
SXT: trimethoprim-sulfamethoxazole, TE: tetracycline, TIC: ticarcillin, TOB: tobramycin
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drugs including 3GC and ﬂuoroquinolones are used 
for treatment of children and adults, respectively (7).
Unfortunately, it has been recently reported that the 
prevalence of resistance to some commonly used 
antibiotics is increasing in Shigella species in Iran 
(22). Class 2 integrons have proved to be at least in 
part responsible for the antibiotic resistance spectrum 
(12).
Beta-lactams are the most frequently used 
antimicrobial agents in Iran and the ESBL 
producer’sorganisms have been reported frequently in 
several bacterial species in this country (23). Recently 





in six Shigella 
strains isolated from patients admitted to Milad 
Hospital, Tehran, Iran (24).
An increase in the occurrence of antimicrobial 
resistance, including resistance to 3GC and 
ﬂuoroquinolones among  Shigella spp. has been 









 genes have been 
reported in Shigella spp. isolates (7, 25, 26).
In our study, the prevalence of ESBL producing 
Shigella isolates, accounting for 7.3% of all Shigella 
isolates identified in the period under study, is higher 
than detection rates observed in many other countries 
(5, 7, 9). Moreover, CMY-59 has never been reported 
in Shigella, whereas CMY-2-type AmpC ß-lactamases 
has been previously detected, but infrequently. 
Recently, the detection of AmpC β-lactamase 
producer strains in Shigella spp. has been reported in 
Iran (24).
Among all ESBL producing strains, only the 
S. flexneri isolate was able to transfer the bla gene 
to transconjugant, indicating it was mediated by a 
plasmid however we did not make further attempts 
to obtain the transfer of resistance determinants. 
This could have resulted from the presence of 
chromosomally-mediated β-lactamase genes in the 
parental strains that could not be transferred to the 
recipients. Alternatively, they can be located on 
large low-copy number plasmids with a low transfer 
frequency. 
A ceftriaxone resistant Shigella strain with a 
plasmid mediated CMY-2 AmpC type ESBL was also 
responsible for a dysentery outbreak in Taiwan (26). 
On the contrary, CTX-M-15 are the most common types 
of cefotaximases identified among Shigella isolates 
(3, 5, 6, 27, 28). Of special concern, plasmid mediated 
production of this β-lactamase is widely disseminated 
in Enterobacteriaceae, particularly among strains 
isolated from nosocomial infections, but more and 
more frequently from community-acquired cases. 
Our findings raise concerns about the dissemination 
of ESBL among the strains of endemic S. sonnei 
throughout the country, because S. sonnei is now 
the most frequently isolated Shigella species in Iran 
and shigellosis by such strains in the community can 
pose a significant threat to patients and presents a 
challenge for disease management. Thus, active and 
continued surveillance of antibacterial drug resistance 
appears to be needed as the first step, along with a 
judicious use of antibiotics, to minimize the spread of 
ESBL producing Shigella isolates. This is  especially 
critical for the pediatric patients for whom antibiotic 
therapeutic options are inherently limited. 
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